Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3598188 | 1.00 | TRPV1 (0.51) | TRPV1EGFRMAPK1HSD17B10RAB9A | |
| SCHEMBL8222368 | 0.99 | TRPV1 (0.50) | TRPV1EGFRMAPK1HSD17B10RAB9A | |
| SCHEMBL3598973 | 0.90 | SMN1; SMN2 (0.50) | TRPV1MAPK1RAB9APOLBALDH1A1 | |
| SCHEMBL1671869 | 0.88 | EGFR (0.53) | EGFRMAPK1HSD17B10RAB9APOLB | |
| SCHEMBL3600241 | 0.88 | TRPV1 (0.53) | TRPV1HSD17B10POLBMAPTHIF1A | |
| SCHEMBL3600239 | 0.88 | TRPV1 (0.53) | TRPV1HSD17B10POLBMAPTHIF1A | |
| SCHEMBL8224018 | 0.86 | TRPV1 (0.52) | TRPV1HSD17B10RAB9APOLBNPC1 | |
| SCHEMBL12802069 | 0.85 | TRPV1 (0.46) | TRPV1POLBMAPT | |
| SCHEMBL3603010 | 0.81 | TRPV1 (0.48) | TRPV1 | |
| SCHEMBL3603012 | 0.81 | TRPV1 (0.48) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010086454-A9 | N-(PHENYL OR PYRIDYL)PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF OBESITY, DIABETES, CARDIOVASCULAR DISEASES AND OTHER ADIPONECTIN-RELATED DISEASES | ZELTIA, S.A. (ES) | 2011-04-28 | — | — | WO | disclosed |
| WO-2010086454-A1 | N-(PHENYL OR PYRIDYL)PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF OBESITY, DIABETES, CARDIOVASCULAR DISEASES AND OTHER ADIPONECTIN-RELATED DISEASES | ZELTIA, S.A. (ES) | 2010-08-05 | — | — | WO | disclosed |
| EP-2213286-A1 | N-(PHENYL OR PYRIDYL)PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF OBESITY, DIABETES AND CARDIOVASCULAR DISEASES | Zeltia, S.A. (ES) | 2010-08-04 | — | — | EP | disclosed |
| EP-2213286-A1 | N-(PHENYL OR PYRIDYL)PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF OBESITY, DIABETES AND CARDIOVASCULAR DISEASES | Zeltia, S.A. (ES) | 2010-08-04 | — | — | EP | disclosed |
| US-20100041665-A1 | N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA, S.A. (ES) | 2010-02-18 | — | — | US | disclosed |
| US-20100041665-A1 | N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA, S.A. (ES) | 2010-02-18 | — | — | US | disclosed |
| WO-2008015240-A1 | N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA, S.A. (ES) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041665-A1 | N-PHENYL-PRENYLAMINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | PNMT, PSEN1, SNCA | TRPV1 1245/4885EGFR 4287/4885MAPK1 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.